Cannabis and Special Risk Populations
Cannabis may not be suitable for all patients.
Cannabis and Special Risk Populations
Cannabis may not be suitable for all patients.
Print PDF

Cannabis may not be suitable for all patients. Several publications from Health Canada, the CFPC, and others, have identified a set of special-risk populations in the context of both medical and recreational cannabis use. 1,2,3,4,5,6,7,8 More Level 1 research is needed on both the therapeutic and adverse effects of cannabis for specific presentations and populations.

This resource provides an overview of the risks of cannabis use in the following commonly-cited populations:

  • Women who are pregnant, breastfeeding, or planning to become pregnant
  • Children and youth under 25 years
  • Individuals with current, past, or family history of psychosis
  • Individuals with current, past, or family history of substance use disorder

This resource also includes a note on cannabis use and the increased risk of psychosis and psychotic disorder in the general population.

Pregnant women and fetuses
  • If a woman consumes cannabis while pregnant, she will expose the fetus to delta-9-tetrahydrocannabinol (THC)—the primary psychoactive component in cannabis—through her bloodstream.6,9
  • A 2016 systematic review and meta-analysis of evidence shows that fetuses exposed to THC are more likely to experience lower birth weight and higher odds of placement in NICU/ICU.10
  • Studies to date suggest that women who consume cannabis during pregnancy may have a greater risk of anemia.10
  • Acute effects of cannabis consumption include a decrease in blood pressure, which may increase the risk of falls causing injury to both mother and fetus. 6
  • Findings from two prospective longitudinal cohort studies show that heavy in utero exposure (at least 5 times per week) to THC can negatively effect children’s neurocognitive development. 9,11,12 These effects include but are not limited to:
    • hyperactivity
    • deficits in memory, verbal and visual reasoning, verbal skills
    • reduced academic achievement
  • There is increasing evidence to support a link between maternal cannabis use in pregnancy and the subsequent initiation and frequency of substance use by children in adolescence.9
  • Studies point to higher instances of negative effects on the fetus when cannabis and tobacco use are combined during pregnancy (compared to either cannabis or tobacco alone).9,13,14

  • Note: Many of the studies of cannabis use during pregnancy consider only one method of cannabis consumption and also have one or more of the following limitations :

  • Not controlled for concurrent use of tobacco and/or alcohol
  • Reliant on self-reported data
  • Cannabis products used are not standard (THC levels vary)
Breastfeeding women
  • THC is stored in fatty tissues and accumulates in breast milk. Recent studies have shown that the THC in breast milk is subsequently metabolized by breastfeeding babies. 6,9,15
  • Several reports indicate that babies exposed to THC in breastmilk may experience negative short-term effects, including: 15,16
    • lethargy
    • reduced muscle tone
    • poor feeding habits
Women attempting to conceive
  • There is limited evidence that suggests cannabis consumption may negatively impact a woman’s ability to conceive by: 6,17,18,19
    • disrupting hormonal regulation and menstrual cycles
    • reducing movement of ova through the oviducts
    • decreasing success of in vitro fertilization.
Under the age of 25
  • The human brain continues to develop until the age of 25. Multiple sources have established that regular cannabis use during adolescence and early adulthood can cause functional and structural changes to the brain, impairing its development. 2, 7, 21, 22, 23, 24
Children
  • Cannabis is not appropriate for medical use in pediatric populations except in very specific circumstances, including certain forms of refractory epilepsy (e.g., Dravet syndrome). 25
  • Cannabis use during adolescence has been associated with:
    • increased risk of cannabis use disorder (approximately one in six) 26, 27
    • increased risk of developing mental health problems, including anxiety, depression, psychosis, and schizophrenia 21, 28, 29, 30, 31, 32
    • increased risk of cognitive deficits and poorer school performance 21, 33, 34
  • Cannabis use has been shown to trigger or amplify a genetic predisposition to psychotic disorders. 8, 35, 36
  • For individuals with a first-degree relative who has a history of psychosis, consuming cannabis on a daily basis could increase the risk of developing a psychotic disorder by up to ten times compared to non-users with a family history of psychosis. 8, 36
  • Of individuals who are treated for psychosis, those who began using cannabis during adolescence and early adulthood experience their first psychotic episode three to six years earlier than those who have never used cannabis. 8, 37, 38
Note on cannabis use and the increased risk of psychosis and psychotic disorder in the general population
  • Cannabis use increases the risk of psychosis and psychotic disorders in all users (not just those with a predisposition to psychosis or psychotic disorders).8, 21, 36, 39, 40
  • Individuals who have used cannabis in their lifetime have a 40% higher risk of developing a psychotic outcome than those who have not used cannabis. 8, 36
Risk Factors for the General Population
Use in Adolescence
  • Individuals who begin using cannabis before the age of 16 have a higher risk of developing psychosis and higher odds of developing a psychotic disorder compared to those who started cannabis use later, or who never used cannabis.7,41,42
  • More than 50% of youth who develop psychotic symptoms from cannabis use will develop a future psychotic disorder.32
Frequent Use
  • There is a direct relationship between frequent cannabis use and the risk of developing psychosis.8,36,42,43
  • Individuals who use cannabis daily are up to three times more likely to be at risk of developing psychotic disorders than those who do not use cannabis.8,42
High THC Potency
  • Individuals who use cannabis products with high-potency THC (>10%) are at a greater risk of experiencing a psychotic episode and a greater risk of developing a psychotic disorder when compared to non-users and cannabis users who consume lower THC products. 42,45
Combined Risks
  • Potency and frequency: Individuals who consume high-potency THC (>10%) cannabis on a daily basis are almost five times more likely to develop a psychiatric disorder compared to non-users.45
  • Potency and age: Individuals who begin using high-potency THC (>10%) cannabis before the age of 16 are two times more likely to develop a psychiatric disorder compared to non-users.45
  • Cannabis can be an addictive substance, and the risk of developing cannabis use disorder is higher for individuals with a current, past, or family history of substance use disorder. 2,46
  • Daily cannabis use, prolonged cannabis use, and cannabis use during adolescence can all further increase the risk of cannabis use disorder. 2, 46
Print PDF
References

1 Hodgson, C, Zacharias R. Who shouldn’t use cannabis?: Evidence Brief. Michael G. DeGroote Centre for Medical Cannabis Research. Hamilton, ON; 2017. [cited 26 Sep 2018].

2 Fischer B, Russell C, Sabioni P, van den Brink W, Le Foll B, Hall W, et al. Lower-Risk Cannabis Use Guidelines: A Comprehensive Update of Evidence and Recommendations. Public Health Policy. 2017;107(8):e1-e12.

3 Kahan M, Srivastava A, Spithoff S, Bromley L. Prescribing smoked cannabis for chronic noncancer pain. Canadian Family Physician. 2014;60:1083-1090.

4 Government of Canada. Is cannabis safe to use? Facts for young adults aged 18-25 years: Cannabis evidence Brief. Health Canada. Ottawa, ON; 2018 [cited 26 Sep 2018].

5 Government of Canada Evidence Brief: Is cannabis safe to use? Facts for youth aged 13-17 years: Cannabis evidence Brief. Health Canada. Ottawa, ON; 2018 [cited 26 Sep 2018].

6 Government of Canada Evidence Brief: Is cannabis safe during preconception, pregnancy, and breastfeeding?: Cannabis evidence Brief. Health Canada. Ottawa, ON; 2018 [cited 26 Sep 2018].

7 Lenroot RK, Giedd JN. Brain development in children and adolescents: Insights from anatomical magnetic resonance imaging. Neurosci Biobehav Rev 2006;30(6):718–29.

8 Government of Canada. Does cannabis use increase the risk of developing psychosis or schizophrenia?: Cannabis evidence brief. Health Canada. Ottawa, ON; 2018 [cited 26 Sep 2018].

9 Porath AJ, Konefal S, Kent P. Clearing the smoke on cannabis: Maternal cannabis use during pregnancy—an update. Ottawa, ON: Canadian Centre on Substance Use and Addiction; 2018 [cited Sep 24 2018].

10 Gunn JK, Rosales CB, Center KE, Nunez A, Gibson SJ, Christ C, Ehiri JE. Prenatal exposure to cannabis and maternal and child health outcomes: A systematic review and meta-analysis.BMJ Open 2016 Apr 5; 6(4):e009986,2015-009986

11 Fried P. Ottawa Prenatal Prospective Study, 1995, 2002.

12 Day N, Richardson G. Maternal Health Practices and Child Development Study, 1991.

13 Chabarria KC, Racusin DA, Antony KM, et al. Marijuana use and its effects in pregnancy. Am J Obstet Gynecol 2016;215:506.e1-7.

14 El Marroun H, Tiemeier H, Steegers E, Jaddoe V, Hofman A, Velhulst FC. Intrauterine cannabis exposure affects fetal growth trajectories: The generation R study. Journal of the American Academy of Child & Adolescent Psychiatry Dec 2009; 48(11): 1173-1181.

15 Liston J. Breastfeeding and the use of recreational drugs--alcohol, caffeine, nicotine and marijuana. Breastfeed Rev 1998 Aug;6(2):27-30.

16 Djulus J, Moretti M, Koren G. Marijuana use and breastfeeding. Can Fam Physician. 2005 Mar 10; 51(3): 349–350.

17 Klonoff-Cohen HS, Natarajan L, Chen RV. A prospective study of the effects of female and male marijuana use on in vitro fertilization (IVF) and gamete intrafallopian transfer (GIFT) outcomes. Am J Obstet Gynecol 2006 Feb;194(2):369-76

18 Brents LK. Marijuana, the endocannabinoid system and the female reproductive system. Yale J Biol Med 2016 Jun 27;89(2):175-91. 15.

19 Sharma R, Biedenharn KR, Fedor JM, Agarwal A. Lifestyle factors and reproductive health: Taking control of your fertility. Reprod Biol Endocrinol 2013 Jul 16;11:66,7827-11-66

20 Gundersen TD, Jorgensen N, Andersson AM, Bang AK, Nordkap L, Skakkebaek NE, Priskorn L, Juul A, Jensen TK. Association between use of marijuana and male reproductive hormones and semen quality: A study among 1,215 healthy young men. Am J Epidemiol 2015 Sep 15;182(6):473-81.

21 Grant CN, Belanger RE, Canadian Paediatric Society, Adolescent Health Committee. Position Statement: Cannabis and Canada’s children and youth. Paediatr Child Health 2017;22(2):98-102. [cited Sep 21 2018].

22 Jacobus J, Tapert SF. Effects of cannabis on the adolescent brain. Curr Pharm Des. 2014;20(13): 2186–2193.

23 Lisdahl KM, Gilbart ER,Wright NE, Shollenbarger S. Dare to delay? The impacts of adolescent alcohol and marijuana use onset on cognition, brain structure, and function. Front Psychiatry. 2013;4:53.

24 Volkow ND, Swanson JM, Evins AE, et al. Effects of cannabis use on human behavior, including cognition, motivation, and psychosis: A Review. Jama Psychiatry 2016 73 (3): 292-97.

25 Rieder MJ. Is the medical use of cannabis a therapeutic option for children? Canadian Pediatric Society Position Statement. Paediatr Child Health 2016; 21 (1): 31-34.

26 Turner SD, Spithoff S, Kahan M. Approach to cannabis use disorder in primary care: Focus on youth and other high-risk users. Can Fam Physician 2014;60(9):801–8, e423–32.

27 Volkow ND, Baler RD, Compton WM, Weiss SR . Adverse health effects of marijuana use. N Engl J Med 2014;370(23):2219–27.

28 Buckner JD, Schmidt NB, Lang AR , Small JW, Schlauch RC, Lewinsohn PM. Specificity of social anxiety disorder as a risk factor for alcohol and cannabis dependence. J Psychiatr Res 2008;42(3):230–9.

29 Cornelius JR , Kirisci L, Reynolds M, Clark DB, Hayes J, Tarter R . PTSD contributes to teen and young adult cannabis use disorders. Addict Behav 2010;35(2):91–4.

30 Johns A. Psychiatric effects of cannabis. Br J Psychiatry 2001;178:116–22.

31 D’Souza DC, Perry E, MacDougall L, et al. The psychotomimetic effects of intravenous delta-9-tetrahydrocannabinol in healthy individuals: Implications for psychosis. Neuropsychopharmacology 2004;29(8):1558–72.

32 Arendt M, Rosenberg R , Foldager L, Perto G, Munk-Jørgensen P. Cannabis-induced psychosis and subsequent schizophrenia-spectrum disorders: Follow-up study of 535 incident cases. Br J Psychiatry 2005;187(6):510–5.

33 Lynskey MT, Coffey C, Degenhardt L, Carlin JB, Patton G. A longitudinal study of the effects of adolescent cannabis use on high school completion. Addiction 2003;98(5):685–92.

34 Brook JS, Stimmel MA, Zhang C, Brook DW. The association between earlier marijuana use and subsequent academic achievement and health problems: A longitudinal study. Am J Addict 2008;17(2):155–60.

35 Large M, Sharma S, Compton MT, Slade T, Nielssen O. Cannabis use and earlier onset of psychosis: A systematic meta-analysis. Arch Gen Psychiatry 2011 Jun;68(6):555-61.

36 Radhakrishnan R, Wilkinson ST, D'Souza DC. . Gone to pot - A review of the association between cannabis and psychosis. Front Psychiatry 2014 May 22;5:54.

37 Di Forti M, Sallis H, Allegri F, Trotta A, Ferraro L, Stilo SA, Marconi A, La Cascia C, Reis Marques T, Pariante C, et al. Daily use, especially of high-potency cannabis, drives the earlier onset of psychosis in cannabis users. Schizophr Bull 2014 Nov;40(6):1509-17.

38 Helle S, Ringen PA, Melle I, Larsen TK, Gjestad R, Johnsen E, Lagerberg TV, Andreassen OA, Kroken RA, Joa I, et al. Cannabis use is associated with 3 years earlier onset of schizophrenia spectrum disorder in a naturalistic, multi-site sample (N=1119). Schizophr Res 2016 Jan;170(1):217-21.

39 Batalla A, Bhattacharyya S, Yucel M, Fusar-Poli P, Crippa JA, Nogue S, Torrens M, Pujol J, Farre M, Martin-Santos R. Structural and functional imaging studies in chronic cannabis users: A systematic review of adolescent and adult findings. PLoS One 2013;8(2):e55821.

40 Moore TH, Zammit S, Lingford-Hughes A et al. Cannabis use and risk of psychotic or affective mental health outcomes: A systematic review. Lancet 2007 Jul; 370 (9584): 319-28.

41 McGrath J, Welham J, Scott J, et al. Association between cannabis use and psychosis-related outcomes using sibling pairanalysis in a cohort of young adults.Arch Gen Psychiatry. 2010;67(5):440–447.

42 Di Forti M, Quattrone D, Freeman TP et al. The contribution of cannabis use to variation in the incidence of psychotic disorder across Europe (EU-GEI): a multicenter case-control study. The Lancet Psychiatry 2019 Mar; 2215-0366(19):30048-3.

43 Marconi A, Di Forti M, Lewis CM, Murray RM, Vassos E. Meta-analysis of the association between the level of cannabis use and risk of psychosis. Schizophr Bull 2016 Feb 15.

44 Fergusson DM, Horwood LJ, Ridder EM. Tests of casual linkages between cannabis use and psychotic symptoms. Addiction 2005 Mar;100(3):354-66.

45 Di Forti M, Morgan C, Dazzan P et al. High-potency cannabis and the risk of psychosis. The British Journal of Psychiatry . 2009 Dec; 195(6):488-491.

46 Government of Canada. Is cannabis addictive? Cannabis evidence Brief. Health Canada. Ottawa, ON; 2018 [cited 4 Apr 2019].



Updated: May 27, 2019